Overexpression of LAPTM4B-35 closely correlated with clinicopathological features and post-resectional survival of gallbladder carcinoma

Eur J Cancer. 2007 Mar;43(4):809-15. doi: 10.1016/j.ejca.2006.10.025. Epub 2007 Feb 5.

Abstract

Gallbladder carcinoma (GBC) is a malignancy with dismal prognosis and unclear gene expression profile. We aimed to first present the expression of LAPTM4B-35, one product of a cancer associated gene recently cloned in hepatocellular carcinoma (HCC), and its correlation with clinicopathological features and prognosis of GBC. Immunohistochemical detection of LAPTM4B-35 was performed on samples from 75 patients with GBC. LAPTM4B-35 protein was overexpressed in 57 patients (76%) with GBC. The staining scores were significantly related to histology type, lymph node involvement, distant metastasis, Nevin staging and differentiation of GBC (P<0.05). Univariate analysis revealed that overall or disease-free survival of patients was inversely associated with its staining scores (P<0.001). Multivariate analysis showed that LAPTM4B-35 staining score was an independent prognostic marker for both overall and disease-free post-resectional survival of GBC (P=0.004 and 0.027, respectively). LAPTM4B-35 overexpressed in a majority of GBCs and correlated with clinicopathological features and post-resectional survival.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Biomarkers, Tumor / metabolism*
  • Disease-Free Survival
  • Female
  • Gallbladder Neoplasms / metabolism*
  • Gallbladder Neoplasms / mortality
  • Gallbladder Neoplasms / pathology
  • Humans
  • Immunohistochemistry
  • Male
  • Membrane Proteins / metabolism*
  • Middle Aged
  • Neoplasm Proteins / metabolism*
  • Oncogene Proteins / metabolism*
  • Postoperative Period

Substances

  • Biomarkers, Tumor
  • LAPTM4B protein, human
  • Membrane Proteins
  • Neoplasm Proteins
  • Oncogene Proteins